Introduction
============

Blood pressure control is a complex process that involves variety of organ systems, such as cardiovascular system, central nervous system, adrenal glands, and kidneys ([@B7]). Several classes of drugs (beta and alpha blockers, angiotensin converting enzyme inhibitors, calcium channel blockers, diuretics, etc.) are currently being used for the treatment of hypertensive patients in order to reduce cases of morbidity and mortality that are associated with cardiovascular diseases ([@B27]). These classes of drugs are often used in combination for several reasons. However, the cases of side effects that are associated with some of these antihypertensive drugs have led to their use limitations for some patients. Hence, there are needs for the development of new drugs with desirable pharmacological and therapeutic profiles to control arterial hypertension ([@B29]).

The 5-(1-(3 fluorophenyl)-1H-pyrazol-4-yl)-2H-tetrazole (LQFM-21) is a newly synthesized pyrazole derivative ([@B34]). The pyrazole compounds are known to possess hypoglycemic, analgesic, anti-inflammatory, antimicrobial, anticonvulsant, antioxidant, and anti-tumor properties ([@B21]; [@B20]; [@B28]; [@B30]; [@B26]). Moreover, recent studies showed that pyrazole derivatives as neural and inducible nitric oxide synthase (nNOS and iNOS) inhibitors ([@B5]), 2,4,5,6-tetrahydrocyclopenta\[c\]pyrazoles as N-type calcium channel inhibitors ([@B44]), vasorelaxant and phosphodiesterase inhibitor ([@B19]).

Previous studies have shown that the new LQFM-21 compound has anti-inflammatory, analgesic, and antinociceptive properties ([@B15], [@B14], [@B16]; [@B12]). Although this prototype elicited vasorelaxant activity in the isolated arteries ([@B34]), the effect of this compound on cardiovascular parameters such as arterial blood pressure, heart rate (HR), and renal and aortic blood flow remains unknown. So, we hypothesized a possible antihypertensive effect of LQFM-21. Therefore, the present study sought to evaluate the antihypertensive and vasodilatory effects of LQFM-21 in spontaneously hypertensive rats (SHR).

Materials and Methods {#s1}
=====================

Animals
-------

All experiments were conducted on adult male SHRs or Wistar normotensive rats (NTRs) (280--350 g). Rats were obtained from the central animal house of the Federal University of Goiás. Experimental procedures were designed in strict adherence to the National Health Institute Guidelines for Care and Use of Laboratory Animals and approved by the Ethics Committee on the Use of Animals of Federal University of Goiás (protocol number 034/12).

Measurement of Systolic Blood Pressure With Tail-Cuff Sphygmomanometer
----------------------------------------------------------------------

Spontaneously hypertensive rat(s) and NTR(s) were acclimatized for about 5--6 h in the laboratory at room temperature. Systolic blood pressure (SBP) and HR were measured with a tail-cuff sphygmomanometer with mercury (Harvard Apparatus, MA, United States) in conscious rats pre-warmed at approximately 37°C. This is a non-invasive and indirect method of measuring SBP. The apparatus set up include a restrainer, a tail cuff containing latex tube, and a dual channel recorder. It is pertinent to acknowledge the inherent limitations such as stress that is associated with the use of tail-cuff sphygmomanometer to measure the pressure of conscious SHR and NTR(s).

The vehicle (10% DMSO and 2% Tween in 0.9% NaCl; i.g.) or LQFM-21 (15 mg kg^-1^) was administrated by intragastric catheter (0.3 mL) 2 h prior to the measurements of SBP and HR every 48 h for 15 days. Data were digitized at a frequency of 2000 samples per second using an analog to digital converter (PowerLab 4/25, ML845, ADInstruments, Bella Vista, NSW, Australia).

Baroreflex Sensitivity Test
---------------------------

The BRS was evaluated through intravenous infusion of phenylephrine (3, 6, and 12 mg kg^-1^; Sigma-Aldrich) and sodium nitroprusside (16, 32, and 64 mg kg^-1^, Sigma-Aldrich) in unanesthetized SHR(s) and NTR(s). BSI index was later calculated as a ratio of changes in HR and MAP.

Surgical Procedures
-------------------

Spontaneously hypertensive rat(s) and NTR(s) were anesthetized with halothane (2--3% in O2; Tanohalo; Cristália, Brazil). The right femoral vein and artery were catheterized for drug administration and blood pressure recording, respectively. After catheterization, anesthesia was maintained by intravenous administration of urethane (1.2 g kg^-1^ b.wt., i.v.; Sigma-Aldrich, St. Louis, MO, United States). The trachea was cannulated to facilitate breathing. Subsequently, rats were placed on stereotactic apparatus and retroperitoneal incisions were performed. Miniature ultrasonic transit time flow probes (Transonic Systems Inc., Ithaca, NY, United States) were placed around the left renal artery and abdominal aorta to record renal blood flow (RBF) and aortic blood flow (ABF), respectively. Body temperature was maintained at 37.0 ± 0.5 °C on a thermostatically controlled bench. Following stabilization of cardiovascular parameters, LQFM-21 (0.05; 0.1; 0.2; 0.4 mg kg^-1^) or vehicle (10% DMSO and 2% Tween in 0.9% NaCl) were randomly administered in SHR(s) and NTR(s).

Recording of Arterial Blood Pressure, Renal and Aortic Blood Flow
-----------------------------------------------------------------

The pulsatile arterial pressure (PAP) was continuously recorded through the arterial cannula that was connected to a pressure transducer (MLT0380, ADInstruments, Bella Vista, NSW, Australia) with an amplifier (Bridge Amp, ML221, ADInstruments, Bella Vista, NSW, Australia). The miniatures probes were placed around left renal artery and thoracic aorta and connected to T206 flowmeter (Transonic Systems, Inc., Ithaca, NY, United States) to record the RBF and ABF, respectively. Data were digitized at a frequency of 2000 samples per second using an analogue to digital converter (PowerLab 4/25, ML845, ADInstruments, Bella Vista, NSW, Australia).

Drugs Administration
--------------------

### Effect of [L]{.smallcaps}-Name (Nitric Oxide Synthase Inhibitor) and Atropine (Muscarinic Receptors Antagonist) Pretreatment

Spontaneously hypertensive rat(s) group (*n* = 8) were pretreated intravenously with [L]{.smallcaps}-Name (0.3 mg kg^-1^, *N~ω~*-nitro-[L]{.smallcaps}-arginine methyl ester hydrochloride, Sigma-Aldrich, nitric oxide synthase inhibitor) prior to the measurement of cardiovascular parameters. In a separate experiment, SHR(s) group (*n* = 8) were pretreated intravenously with atropine (0.9 mg kg^-1^, muscarinic receptors antagonist) prior to the measurement of cardiovascular parameters.

Isolated Aortic Ring Preparation
--------------------------------

In other group (*n* = 5), isolated aortic rings of the SHR(s) were used to evaluate the effects of LQFM-21 in rat thoracic aorta. Aortic rings (4 mm) were placed in 9-mL organ bath chambers containing Krebs--Henseleit solution \[NaCl (118.06 mmol L^-1^), KCl (4.6 mmol L^-1^), NaHCO~3~ (24.9 mmol L^-1^), MgSO~4~.7H~2~O (2.4 mmol L^-1^), CaCl~2~.2H~2~O (3.3 mmol L^-1^), KH~2~PO~4~ (0.9 mmol L^-1^), and glucose (11.1 mmol L^-1^)\] and constant supply of 95% O~2~ and 5% CO~2~ at 37°C. The aortic rings were maintained under a tension of 1.5 g for 1 h to equilibrate. Mechanical activity was recorded isometrically using a data acquisition system (DATAQ Instruments). The effects of LQFM-21 (10^-6^--10^-3^ mol L^-1^) were evaluated in aortic rings \[with (E+) or without (E-) endothelium\] pre-constricted with phenylephrine (0.1μmol L^-1^). Endothelial integrity was tested with acetylcholine (ACh, 10^-6^ mol L^-1^) in rings previously contracted with Phe (10^-7^mol L^-1^). A relaxation of 80% or more indicated the functional integrity of the endothelium. In order to investigate the action mechanism involved in the effects of LQFM-21, the vessels were pre-treated for 30 min with ODQ (1H-\[1,2,4\]oxadiazolo\[4,3-a\]quinoxalin-1-one, Sigma-Aldrich, soluble guanylyl cyclase inhibitor) or [L]{.smallcaps}-NAME (nitric oxide synthase inhibitor).

Data Analysis
-------------

Mean arterial pressure (MAP) was calculated with weighted average from PAP signal (2/3 diastolic pressure + 1/3 systolic pressure) using the software PowerLab 4/25 (ML845, ADInstruments, Bella Vista, NSW, Australia). HR was calculated as instantaneous frequency from the PAP signal (PowerLab 4/25, ML845, ADInstruments, Bella Vista, NSW, Australia). Changes in RBF and ABF were calculated as the percentage relative ratio to baseline (% RBF and % ABF). The renal vascular conductance (RVC) and aortic vascular conductance (AVC) were obtained by the ratio of RBF MAP^-1^ and ABF MAP^-1^, respectively. The variations in RVC and AVC were expressed as percentage of change from baseline value (% RVC and % AVC). Statistical analysis was performed using GraphPad Prism version 6.01 (GraphPad Software Inc., San Diego, CA, United States). Data were analyzed by two-way analysis of variance followed by Newman--Keuls *post-test*. The differences in baseline and BSI between groups were analyzed using unpaired Student's *t*-test. A value of *p* \< 0.05 was considered significant.

Results
=======

Effects of Chronic Treatment With LQFM-21 on SBP and HR in Unanesthetized SHR and NTR
-------------------------------------------------------------------------------------

The SHR group (*n* = 10) treated with LQFM-21 (15 mg kg^-1^, i.g.) showed a decrease in SBP, on the 3rd, 5th, 7th, and 9th day of treatment (152.9 ± 3.9; 147.6 ± 3.6; 154.2 ± 4.2; 156.0 ± 2.5 mmHg, respectively, *p* \< 0.05; **Figure [1A](#F1){ref-type="fig"}**) as compared to the baseline (173.2 ± 3.5 mmHg) and to the vehicle (168.2 ± 3.0; 171.1 ± 1.8; 168.0 ± 3.0; 169.3 ± 3.0, respectively; *p* \< 0.05; **Figure [1A](#F1){ref-type="fig"}**). The treatment did not alter HR value (**Figure [1B](#F1){ref-type="fig"}**).

![Systolic blood pressure (SBP) in SHR **(A)** and NTR **(C)** unanesthetized animals. Heart rate (HR) in SHR **(B)** and NTR **(D)** unanesthetized animals. Days 0--1 shown values baseline (SBP) while days 1--9 show measurements (every 48 h) SBP values following daily oral administration of the vehicle or LQFM-21 (15 mg⋅kg^-1^). Data are expressed as mean ± SEM (*n* = 10). ^∗^Values significantly different from baseline; ^+^compared to vehicle; *p* \< 0.05.](fphys-09-01073-g001){#F1}

The NTR(s) (*n* = 10) treated with LQFM-21 (15 mg kg^-1^, i.g.) showed a decrease in SBP, only the 7th and 9th day of treatment (102.4 ± 1.6 and 93.2 ± 2.6 mmHg, respectively, *p* \< 0.05; **Figure [1C](#F1){ref-type="fig"}**) as compared to the baseline (128.7 ± 3.7 mmHg) and to the vehicle (123.3 ± 2.5 and 120.0 ± 1.8, respectively; *p* \< 0.05; **Figure [1C](#F1){ref-type="fig"}**). The treatment did not alter HR value (**Figure [1D](#F1){ref-type="fig"}**).

The pre-treatment with LQFM-21 (15 mg kg^-1^, i.g.) did not cause significant changes in the BRS after phenylephrine infusion in SHR(s) (LQFM-21: -1.9 ± 0.2 vs. vehicle: -1.9 ± 0.3 mmHg bpm^-1^; **Figure [2A](#F2){ref-type="fig"}**; *n* = 4) and NTR(s) (LQFM-21: -1.9 ± 0.4 vs. vehicle: -2.1 ± 0.3 mmHg bpm^-1^; **Figure [2C](#F2){ref-type="fig"}**; *n* = 4). In addition, the pre-treatment with LQFM-21 (15 mg kg^-1^, i.g.) did not cause significant changes in the BRS after infusion of sodium nitroprusside in SHRs (LQFM-21: -3.9 ± 0.6 vs. -4.1 ± 0.2 bpm mmHg^-1^; **Figure [2B](#F2){ref-type="fig"}**; *n* = 4) or in NTR(s) (LQFM-21: -3.1 ± 0.3 vs. -3.2 ± 0.0 bpm mmHg^-1^; **Figure [2D](#F2){ref-type="fig"}**; *n* = 4).

![Baroreflex index (BI) of SHR **(A,C)** and NTR **(B,D)** animals induced by phenylephrine and sodium nitroprusside infusions. Vehicle (∙) and LQFM-21 (15 mg⋅kg^-1^) (∙). Data are expressed as mean ± SEM (*n* = 4), with their standard errors represented by vertical bars; *p* \< 0.05.](fphys-09-01073-g002){#F2}

Effects of Acute Intravenous Infusion of LQFM-21 on MAP, HR, RVC, and AVC in Anesthetized SHR and Normotensive Rats
-------------------------------------------------------------------------------------------------------------------

The typical tracing shows the cardiovascular changes promoted by dose-dependent LQFM-21 administration in SHR (**Figure [3A](#F3){ref-type="fig"}**). Intravenous administration of LQFM-21 (0.05, 0.1, 0.2, and 0.4 mg kg^-1^) in SHR(s) (*n* = 6) reduced MAP (Δ MAP: -16.8 ± 2.9; -19.5 ± 2.4; -22.0 ± 3.8; -26.6 ± 6.4 mmHg, respectively, *p* \< 0.05; **Figure [3B](#F3){ref-type="fig"}**). LQFM-21 (0.4 mg kg^-1^) reduced HR (ΔHR: -11.2 ± 0.8 bpm, *p* \< 0.05; **Figure [3C](#F3){ref-type="fig"}**). The infusion of LQFM-21 (0.2 mg kg^-1^) increased RVC (Δ% RVC: 22.0 ± 8.8%, *p* \< 0.05; **Figure [3D](#F3){ref-type="fig"}**) and AVC at doses 0.05, 0.1, 0.2, and 0.4 mg kg^-1^ (Δ% AVC: 12.2 ± 2.1; 13.8 ± 5.6; 18.2 ± 2.3; 15.6 ± 3.1, respectively, *p* \< 0.05, **Figure [3E](#F3){ref-type="fig"}**).

![**(A)** Typical tracing of changes in cardiovascular parameters induced by intravenous injection of vehicle or LQFM-21 in anaesthetized SHR. Dashed line indicates the vehicle or LQFM-21 infusion. **(B)** Mean arterial pressure (MAP), **(C)** Heart rate (HR), **(D)** renal vascular conductance (RVC), **(E)** aortic vascular conductance (AVC) in anaesthetized SHR from the response to infusions of vehicle (∙) and LQFM-21 (∙) at doses 0.05, 0.1, 0.2, 0.4 mg⋅kg^-1^. Data are expressed as mean ± SEM, with their standard errors represented by vertical bars (*n* = 6). ^∗^Values significantly different from treated with vehicle; *p* \< 0.05.](fphys-09-01073-g003){#F3}

The typical tracing shows the cardiovascular changes promoted by dose-dependent LQFM-21 administration in NTR(s) (**Figure [4A](#F4){ref-type="fig"}**). Intravenous administration of LQFM-21 (0.05, 0.1, 0.2, and 0.4 mg kg^-1^) in these rats (*n* = 6) reduced MAP (ΔMAP: -9 ± 1.3; -21.5 ± 2.8; -21.5 ± 2.8; -17.2 ± 2.7 mmHg, respectively, *p* \< 0.05; **Figure [4B](#F4){ref-type="fig"}**). LQFM-21 (0.4 mg kg^-1^) did not change HR (ΔHR: -2.3 ± 1.6 bpm, *p* \< 0.05; **Figure [4C](#F4){ref-type="fig"}**). The infusion of LQFM-21 increased RVC (ΔRVC: 12 ± 1.9; 23.2 ± 3.2; 26.8 ± 6.3; 34.8 ± 5.9 mmHg, respectively, *p* \< 0.05; **Figure [4D](#F4){ref-type="fig"}**) and AVC at doses 0.05, 0.1, 0.2, and 0.4 mg kg^-1^ (Δ% AVC: 17.3 ± 1.7; 27.8 ± 2.6; 32.7 ± 4.8; 42.2 ± 3.4%, respectively, *p* \< 0.05, **Figure [4E](#F4){ref-type="fig"}**).

![**(A)** Typical tracing of changes in cardiovascular parameters induced by intravenous injection of vehicle or LQFM-21 in anaesthetized NTR. Dashed line indicates the vehicle or LQFM-21 infusion. **(B)** Mean arterial pressure (MAP), **(C)** Heart rate (HR), **(D)** renal vascular conductance (RVC), **(E)** aortic vascular conductance (AVC) in anaesthetized NTR from the response to infusions of vehicle (∙) and LQFM-21 (∙) at doses 0.05, 0.1, 0.2, 0.4 mg⋅kg^-1^. Data are expressed as mean ± SEM, with their standard errors represented by vertical bars (*n* = 6). ^∗^Values significantly different from treated with vehicle, *p* \< 0.05.](fphys-09-01073-g004){#F4}

Effects of the Nitric Oxide Synthetase Inhibitor on Antihypertensive Response Induced by Acute Infusion of LQFM-21 in Anesthetized SHR
--------------------------------------------------------------------------------------------------------------------------------------

The pretreatment with [L]{.smallcaps}-NAME attenuated the effect of LQFM-21 on MAP (ΔMAP: -2.4 ± 4.0 mmHg, *p* \> 0.05; **Figure [5A](#F5){ref-type="fig"}**; *n* = 6) and HR (ΔHR: -6.8 ± 8.7 bpm, *p* \> 0.05; **Figure [5B](#F5){ref-type="fig"}**). Renal and aortic vasodilation caused by LQFM-21 was abolished by the pretreatment with [L]{.smallcaps}-NAME (Δ% RVC: -2.2 ± 8.2%; Δ% AVC: -5.6 ± 3.8%, *p* \> 0.05; **Figures [5C,D](#F5){ref-type="fig"}**).

![**(A)** Mean arterial pressure (MAP), **(B)** Heart rate (HR), **(C)** renal vascular conductance (RVC), **(D)** aortic vascular conductance (AVC) in anaesthetized rats SHR from the response to infusions of vehicle; LQFM-21 (0.4 mg kg^-1^) and LQFM-21 + [L]{.smallcaps}-NAME. Data are expressed as mean ± SEM, with their standard errors represented by vertical bars (*n* = 8). ^∗^Values significantly different from vehicle; ^†^mean values was significantly different from LQFM-21; *p* \< 0.05.](fphys-09-01073-g005){#F5}

Effects of the Muscarinic Receptors Antagonist on Antihypertensive Response Induced by Acute Infusion of LQFM-21 Anesthetized in SHR
------------------------------------------------------------------------------------------------------------------------------------

The LQFM-21-induced decrease in MAP and HR was blocked by atropine (ΔMAP: 4.1 ± 2.4 mmHg; ΔHR: 1.6 ± 2.2 bpm, *p* \> 0.05; **Figures [6A,B](#F6){ref-type="fig"}**; *n* = 6). The renal and aortic vasodilation caused by LQFM-21 was inhibited by atropine (Δ% RVC: -3.3 ± 2.0%; Δ% AVC: -2.1 ± 1.8%, *p* \> 0.05; **Figures [6C,D](#F6){ref-type="fig"}**).

![**(A)** Mean arterial pressure (MAP), **(B)** Heart rate (HR), **(C)** renal vascular conductance (RVC), **(D)** aortic vascular conductance (AVC) in anaesthetized rats SHR from the response to infusions of vehicle; LQFM-21 (0.4 mg kg^-1^) and LQFM-21 + atropine. Data are expressed as mean ± SEM, with their standard errors represented by vertical bars (*n* = 8). ^∗^Values significantly different from vehicle; ^†^mean values was significantly different from LQFM-21; *p* \< 0.05.](fphys-09-01073-g006){#F6}

Effect of Guanylyl Cyclase Inhibitor on Vasorelaxation Induced by LQFM-21 in Isolated Aortic Rings of SHR
---------------------------------------------------------------------------------------------------------

As shown in **Figure [7A](#F7){ref-type="fig"}**, LQFM-21 induced an endothelium-dependent vascular relaxation (maximal response: 54.4 ± 3.8%, *p* \< 0.05; *n* = 5). In endothelium-denuded aorta, LQFM-21 induced only a slight relaxation (maximal response: 11.2 ± 2.7%, *p* \> 0.05; **Figure [7A](#F7){ref-type="fig"}**). The vasorelaxation effect of LQFM-21 was blocked by ODQ (30.2 ± 3.9%, *p* \> 0.05; **Figure [7B](#F7){ref-type="fig"}**) or [L]{.smallcaps}-NAME (20.7 ± 0.6%, *p* \> 0.05; **Figure [7B](#F7){ref-type="fig"}**).

![**(A)** Effects of LQFM-21 in aortic rings (E+) or without endothelium (E-), **(B)** effect LQFM-21 on aortic rings of SHR in the absence or presence of [L]{.smallcaps}-NAME (10^-6^ mol L^-1^) or ODQ (3.10^-6^ mol L^-1^). Data are expressed as mean ± SEM, (*n* = 5). ^∗^Values significantly different from LQFM-21; *p* \< 0.05.](fphys-09-01073-g007){#F7}

Discussion
==========

The limitations of current antihypertensive therapies have stimulated research and development of new classes of drugs. Some of these new drugs could facilitate better control of blood pressure, high tolerability, and effective prevention of cardiovascular diseases ([@B32]; [@B37]). Synthesis and modification of compounds remain a feasible alternative strategy for new drug development strategies ([@B45]). Previous data on pyrazole derivatives on voltage-dependent calcium channels ([@B44]) and vascular function ([@B5]; [@B34]) suggested potential hemodynamic actions of these class of compounds. However, no study has been conducted in an experimental model of essential hypertension before showed an antihypertensive property of these compounds. So, the present study evaluated the hypotensive property of LQFM-21 and the possible mechanisms of action underlying its hypotensive effects.

To address these aims, the SHR model of hypertension, a gold standard for experimentally studying essential hypertension, was used to investigate the antihypertensive effect of LQFM-21. The spontaneous rise in the blood pressure of SHR shares common characteristics to human hypertension ([@B25]; [@B40]). Hypertension in SHR has been attributed to an increase in sympathetic adrenergic activity ([@B25]; [@B2]). [@B1] demonstrated that β-adrenoceptor-mediated relaxation of the aortic rings in SHR pre-treated with norepinephrine was less than that of NTRs. This difference was associated with impaired endothelial function.

In the present study, intravenous administration of LQFM-21 caused a decrease in MAP, and an increase in vascular conductance in hypertensive and normotensive animals. In addition, chronic oral treatment this compound decreased SBP significantly as compared to vehicles treated groups. Moreover, in SHR models, the blockade of cardiovascular effects of this compound produced by [L]{.smallcaps}-NAME and atropine suggest the involvement of nitric oxide synthase and muscarinic receptors in its antihypertensive mechanisms. Furthermore, ACh/NO/cGMP pathway could be proposed as the underlining mechanism for the hypotensive and antihypertensive effects elicited by LQFM-21. This is in agreement with [@B18] where authors demonstrated that the NDBP, a new organic nitrate, also reduces blood pressure *via* activation of Ach receptors in both the heart and the vessels.

Atropine is a non-selective antagonist of muscarinic receptors with wide applications particularly as a research tool. In the present study, atropine at the dose of 0.15 mg/kg attenuated the effect of LQFM-21 and thereby suggest the involvement of muscarinic receptors. Subtypes of muscarinic receptors may be linked to excitatory G proteins (M1, M3, and M5), as well as to inhibitory G proteins (M2 and M4). Parasympathetic stimulation and circulating substances often activate muscarinic receptors to elicit reduction of cardiac frequency, force of cardiac contraction, and relaxation of peripheral blood vessels ([@B42]). The reduction in these parameters have been associated with the mechanism of antihypertensive drugs. Both cardiac and vascular functions of drugs are important to antihypertensive effects ([@B41]).

The circulating substances and M3 receptors (with greater expression in blood vessels) interaction could activate Gq which in turn induces the activation of phospholipase C. These events promote the hydrolysis of membrane phosphoinositides to diacylglycerol and inositol triphosphate ([@B36]) to induce vasodilation. On the other hand, the activation of inhibitory G protein-bound muscarinic receptor such as M2 (M2 receptor with higher expression in the heart) ([@B6]) inactivate adenyl cyclase and reduce intracellular levels of cyclic AMP. In addition, studies showed an action of M2 receptors with the activation of endothelium nitric oxide synthase (eNOS) in cardiomyocytes of several mammalian species ([@B13]; [@B35]). Altogether, the signaling pathways involving muscarinic receptors remain important pharmacological targets in the treatment of hypertension.

Currently, over two-thirds of hypertensive cases cannot be treated on just one drug and requires a combination of antihypertensive agents selected from different drug classes ([@B31]; [@B24]; [@B9]; [@B10]; [@B3]). The comparison of "newer" classes of agents, including calcium channel blockers (amlodipine, felodipine, isradipine, nicardipine, nifedipine, and nisoldipine), angiotensin converting enzyme inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril), alpha-1 receptor blocker (doxazosin, prazosin, and terazosin), and aldosterone receptor blockers (eplerenone and spironolactone), with the "older" diuretics (chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, and metolazone), and/or beta blockers (atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, and timolol) ([@B24], [@B23], [@B22]; [@B4]; [@B10]; [@B38]; [@B3]; [@B43]) showed that newer classes were neither superior nor inferior to the older ones.

Hence, our findings, which implicate the involvement of nitric oxide synthase and muscarinic receptors in MAP reduction and vasodilatation effect of LQFM-21, provide potential therapeutic windows for the treatment of some hypertensive patients as a monotherapy or in combination with other classes of antihypertensive drugs. This could be of clinical interest in terms of the dose requirement and faster therapeutic effect with little or no side effects. Rapid therapeutic effects of LQFM-21 could greatly improve patient adherence to prescription.

In addition to the mechanisms involved in the vascular function, some antihypertensive drugs could interfere with normal baroreceptors function ([@B39]) to regulate blood pressure. The reflex response induced by baroreceptor modulates sympathetic activity to the heart, blood vessels, and adrenal medulla. Stimulation of baroreceptors often results in a decrease in sympathetic tone to heart and blood vessels ([@B8]). In the present study, the oral chronic administration of LQFM-21 did not alter baroreceptor reflex sensitivity in SHR. This result rule out the involvement of baroreflex pathways.

Moreover, LQFM-21 induced vascular relaxation in isolated aortic rings of SHR. These data suggest a direct effect of this compound on blood vessel. Of note, the vasorelaxation induced by LQFM-21 was blocked by nitric oxide synthase and guanylate cyclase inhibitors. This result is consistent with current *in vivo* blockade of cardiovascular effect by [L]{.smallcaps}-NAME. Hence, the vascular effect of this compound could be attributed to NO/cGMP mechanism. Other studies seeking for new compounds have also documented that the NO/cGMP pathway is involved in the hypotensive effect of those compounds ([@B17]; [@B11]; [@B33]).

Taken together, our results present the first *in vivo* and *ex vivo* antihypertensive and vasorelaxation effects of LQFM-21. These findings suggest the involvement of nitric oxide and muscarinic receptors in the antihypertensive effects of this compound. However, further studies are required to confirm its therapeutic efficacy and safety profile of LQFM-21.
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